MX2017003366A - Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265). - Google Patents
Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265).Info
- Publication number
- MX2017003366A MX2017003366A MX2017003366A MX2017003366A MX2017003366A MX 2017003366 A MX2017003366 A MX 2017003366A MX 2017003366 A MX2017003366 A MX 2017003366A MX 2017003366 A MX2017003366 A MX 2017003366A MX 2017003366 A MX2017003366 A MX 2017003366A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- depression
- val66met
- methods
- dosing regimens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
La presente invención está dirigida a métodos y regímenes de dosificación para el tratamiento de la depresión (preferentemente, la depresión resistente al tratamiento), para el tratamiento de la depresión en un paciente suicida y/o para el tratamiento y/o la prevención de la tendencia al suicidio (p. ej., ideaciones suicidas), que comprenden el genotipaje de un paciente para determinar su polimorfismo Va166Met rs6265 en el BDNF y la administración de una ketamina, preferentemente esketamina, preferentemente esketamina intranasal, de conformidad con un régimen de dosificación adaptado al genotipo del paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462050439P | 2014-09-15 | 2014-09-15 | |
PCT/US2015/049961 WO2016044150A1 (en) | 2014-09-15 | 2015-09-14 | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017003366A true MX2017003366A (es) | 2018-02-01 |
Family
ID=54200096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003366A MX2017003366A (es) | 2014-09-15 | 2015-09-14 | Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265). |
Country Status (11)
Country | Link |
---|---|
US (5) | US20160074340A1 (es) |
EP (2) | EP3193853A1 (es) |
JP (2) | JP2017528483A (es) |
KR (1) | KR20170054470A (es) |
CN (1) | CN107208133A (es) |
AU (1) | AU2015318123A1 (es) |
CA (1) | CA2961208A1 (es) |
IL (2) | IL251068A0 (es) |
MA (1) | MA40620A (es) |
MX (1) | MX2017003366A (es) |
WO (1) | WO2016044150A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3636251B1 (en) | 2013-03-15 | 2022-01-19 | Janssen Pharmaceutica NV | Pharmaceutical composition of s-ketamine hydrochloride |
EP3193853A1 (en) | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
CA3017749A1 (en) * | 2016-03-18 | 2017-09-21 | Takeda Pharmaceutical Company Limited | Method for identifying clinical trial responders from a placebo group in major depression |
CN110167541A (zh) * | 2016-10-27 | 2019-08-23 | 国立大学法人千叶大学 | (s)-去甲氯胺酮及其盐作为药物的应用 |
RU2020123893A (ru) * | 2017-12-22 | 2022-01-24 | Янссен Фармасьютикалз, Инк. | Эскетамин для лечения депрессии |
EP3813807A1 (en) * | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
JP2022504036A (ja) | 2018-10-05 | 2022-01-13 | クレキシオ バイオサイエンシーズ エルティーディー. | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
EP3934632A4 (en) | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | ESKETAMINE FOR THE TREATMENT OF DEPRESSION |
AU2020271853A1 (en) * | 2019-04-09 | 2021-11-25 | Vistagen Therapeutics, Inc. | Genetic variants associated with response to treatment of neurological disorders |
EP4021432A4 (en) * | 2019-08-28 | 2023-08-16 | Janssen Pharmaceuticals, Inc. | ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY |
KR102312387B1 (ko) * | 2019-11-15 | 2021-10-13 | 이화여자대학교 산학협력단 | 인지 증강을 위한 개인 맞춤형 경두개 직류 자극 프로토콜 생성 방법 및 장치 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
USD308100S (en) | 1987-08-28 | 1990-05-22 | Schering Corporation | Nasal spray pump |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
DE69629108T2 (de) | 1995-02-24 | 2004-04-22 | Weg, Stuart L. | Anwendung von ketamin zur entgiftung |
CA2230690C (en) | 1995-08-30 | 2008-12-23 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
USD401323S (en) | 1996-01-23 | 1998-11-17 | Ing. Erich Pfeiffer Gmbh | Medication dispensing apparatus |
DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
AU135762S (en) | 1998-01-09 | 1998-11-19 | Astrazeneca Ab | Sprayer |
USD433123S (en) | 1998-07-09 | 2000-10-31 | Zeneca Limited | Nasal spray |
ES2238843T3 (es) | 1998-07-24 | 2005-09-01 | Seo Hong Yoo | Disoluciones acuosas transparentes de acidos biliares. |
US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
US6572849B2 (en) | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
USD471973S1 (en) | 2001-08-08 | 2003-03-18 | N.V. Organon | Applicator for a nasal delivery device |
EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
EP1567145B1 (en) | 2002-11-18 | 2009-06-03 | Yaupon Therapeutics, Inc. | Analgesic uses of (s)-norketamine |
US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US8082173B2 (en) | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
USD544957S1 (en) | 2005-03-23 | 2007-06-19 | Rexam Dispensing Systems | Nasal spray dispenser |
US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
CA111438S (fr) | 2005-05-23 | 2006-12-22 | Rexam Dispensing Sys | Pulvérisateur nasal |
JP5026411B2 (ja) | 2005-06-01 | 2012-09-12 | エスエイチエル グループ エービー | 薬物送達装置 |
US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
KR20090029690A (ko) | 2006-03-22 | 2009-03-23 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 우울증을 치료하기 위한 케타민의 투여 방법 |
WO2007123945A2 (en) | 2006-04-21 | 2007-11-01 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
JP2009538331A (ja) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
US20100095957A1 (en) | 2007-03-02 | 2010-04-22 | Corbco, Inc. | Manually operated monodose nasal sprayer device |
US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
USD610678S1 (en) | 2009-03-31 | 2010-02-23 | Daikyo Seiko, Ltd. | Syringe plunger and proximal end of a syringe barrel for a pre-filled nasal drip device |
USD610253S1 (en) | 2009-03-31 | 2010-02-16 | Daikyo Seiko, Ltd. | Pre-filled nasal drip device |
US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
SI2582366T1 (sl) | 2010-06-15 | 2016-02-29 | Gruenenthal Gmbh | Farmacevtska kombinacija za zdravljenje bolečine |
USD699342S1 (en) | 2011-03-09 | 2014-02-11 | Suzuken Company Limited | Injector |
WO2013003669A2 (en) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
USD697201S1 (en) | 2011-07-01 | 2014-01-07 | R5 Pharmaceuticals Limited | Buccal delivery device adaptor |
US20130056557A1 (en) | 2011-09-02 | 2013-03-07 | Maggie Blair Felder | Non-pressurized flavored liquid oxygen breath spray device |
CN109793725B (zh) | 2011-10-14 | 2023-07-25 | 美国政府健康及人类服务部 | 治疗忧郁症和神经性疼痛的药物组合物及其应用 |
RU2622082C2 (ru) | 2011-11-14 | 2017-06-09 | Нестек С.А. | Анализы и способы выбора режима лечения пациента с депрессией |
US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
US20130236573A1 (en) | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
JP2015512418A (ja) | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
JP6722453B2 (ja) | 2012-08-23 | 2020-07-15 | スチュアート エル ウェグ | 抗不安薬組成物、製剤および使用方法 |
FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
ES2484068B1 (es) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
US20140263457A1 (en) | 2013-03-15 | 2014-09-18 | Launce R. Barber | Child-resistant closure systems for containers |
US20140263456A1 (en) | 2013-03-15 | 2014-09-18 | Launce R. Barber | Child-resistant closure systems for containers |
KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
US9569220B2 (en) | 2013-10-06 | 2017-02-14 | Synopsys, Inc. | Processor branch cache with secondary branches |
CN103705909A (zh) | 2013-12-16 | 2014-04-09 | 陈镜伊 | 一种无痛人流用药 |
WO2015101693A1 (es) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas |
EP3094312B1 (en) | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
ES2743699T3 (es) | 2014-04-17 | 2020-02-20 | Develco Pharma Schweiz Ag | Forma de dosificación oral de ketamina |
FR3023188B1 (fr) | 2014-07-04 | 2016-08-19 | Aptar France Sas | Dispositif de distribution de produit fluide. |
JP6545788B2 (ja) | 2014-08-13 | 2019-07-17 | ヤンセン ファーマシューティカ エヌ.ベー. | うつ病の治療方法 |
EP3193853A1 (en) | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
US20180015054A1 (en) | 2014-12-31 | 2018-01-18 | Icahn School Of Medicine At Mount Sinai | Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium |
CN104798728A (zh) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | 产后抑郁动物模型的建立方法及其应用 |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
RU2020123893A (ru) | 2017-12-22 | 2022-01-24 | Янссен Фармасьютикалз, Инк. | Эскетамин для лечения депрессии |
-
2015
- 2015-09-14 EP EP15771377.7A patent/EP3193853A1/en not_active Withdrawn
- 2015-09-14 MA MA040620A patent/MA40620A/fr unknown
- 2015-09-14 US US14/853,351 patent/US20160074340A1/en not_active Abandoned
- 2015-09-14 MX MX2017003366A patent/MX2017003366A/es unknown
- 2015-09-14 CA CA2961208A patent/CA2961208A1/en not_active Abandoned
- 2015-09-14 WO PCT/US2015/049961 patent/WO2016044150A1/en active Application Filing
- 2015-09-14 KR KR1020177009738A patent/KR20170054470A/ko not_active Application Discontinuation
- 2015-09-14 EP EP20157899.4A patent/EP3725307A1/en not_active Withdrawn
- 2015-09-14 JP JP2017514503A patent/JP2017528483A/ja active Pending
- 2015-09-14 CN CN201580061885.9A patent/CN107208133A/zh active Pending
- 2015-09-14 AU AU2015318123A patent/AU2015318123A1/en not_active Abandoned
-
2017
- 2017-03-09 IL IL251068A patent/IL251068A0/en unknown
-
2019
- 2019-12-26 US US16/727,594 patent/US10869844B2/en active Active
-
2020
- 2020-11-26 JP JP2020196076A patent/JP2021054829A/ja active Pending
- 2020-12-01 IL IL279119A patent/IL279119A/en unknown
- 2020-12-21 US US17/129,508 patent/US11173134B2/en active Active
-
2021
- 2021-06-11 US US17/345,395 patent/US11311500B2/en active Active
-
2022
- 2022-04-22 US US17/726,931 patent/US20230089113A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230089113A1 (en) | 2023-03-23 |
EP3725307A1 (en) | 2020-10-21 |
US11173134B2 (en) | 2021-11-16 |
US20160074340A1 (en) | 2016-03-17 |
US10869844B2 (en) | 2020-12-22 |
EP3193853A1 (en) | 2017-07-26 |
CN107208133A (zh) | 2017-09-26 |
US11311500B2 (en) | 2022-04-26 |
US20200246279A1 (en) | 2020-08-06 |
US20210106545A1 (en) | 2021-04-15 |
JP2017528483A (ja) | 2017-09-28 |
AU2015318123A1 (en) | 2017-03-30 |
US20210308076A1 (en) | 2021-10-07 |
IL279119A (en) | 2021-01-31 |
KR20170054470A (ko) | 2017-05-17 |
IL251068A0 (en) | 2017-04-30 |
WO2016044150A1 (en) | 2016-03-24 |
CA2961208A1 (en) | 2016-03-24 |
JP2021054829A (ja) | 2021-04-08 |
MA40620A (fr) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017003366A (es) | Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265). | |
PH12017502103A1 (en) | Methods and kits for treating depression | |
MA40462A (fr) | Méthode de traitement de la dépression | |
MX2018005107A (es) | Composiciones y metodos para la terapia relacionada con la microbiota fecal. | |
MX2015012520A (es) | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. | |
TWD183457S (zh) | 划船運動裝置 | |
TWD182555S (zh) | 運動器材之部分 | |
MX2015017953A (es) | Metodos para tratar el virus de hepatitis c. | |
PH12016500492A1 (en) | Pyridazinone compounds and uses thereof | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
EA201691314A1 (ru) | Терапевтические способы и композиции | |
MX2017000582A (es) | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). | |
EP3212658A4 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
TWD177754S (zh) | 運動腳踏車腳柱 | |
TWD178454S (zh) | 運動腳踏車之部分 | |
BR112019004594A2 (pt) | terapia genética para pacientes com anemia de fanconi | |
MX2017006953A (es) | Medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
PH12014502551A1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
TWD177753S (zh) | 運動腳踏車把手 | |
TN2017000174A1 (en) | Low dosage a2a antagonist for the treatment of adhd and parkinsons | |
CY1121275T1 (el) | Θεραπεια των διαταραχων του εθισμου και του ελεγχου της παρορμητικοτητας χρησιμοποιωντας αναστολεις pde7 | |
BR112017028488A2 (pt) | métodos para tratar hcv | |
PLOS ONE Staff | Correction: Impaired Expression of Type I and Type II Interferon Receptors in HCV-Associated Chronic Liver Disease and Liver Cirrhosis | |
Akashi | Carboplatin/docetaxel/leuprorelin |